Please assess the completion status of the following clinical trial:

Trial Title: Ezetimibe and Statins on Postprandial Lipemia in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes since at least two years~* Stable metabolic control (HbA1c\<8.0%) for at least six months on diet or diet+oral hypoglycemic drugs (insulin secretagogues or metformin), not to be changed during the study period.~* BMI\<30 kg/m2 and body weight stable during the last six months.~* Both sexes; only post-menopausal women.~* LDL-cholesterol \>130 mg/dl, plasma triglycerides \<400 mg/dl.~* No use of hypolipidemic drugs in the last three months.~Exclusion Criteria:~* Patient with renal (serum creatinine \>1.5 mg/dl) or hepatic (serum transaminases \>three times upper normal values) impairment.~* Patients with history of cardiovascular disease.~* Pre-menopausal women.~* Any other acute or chronic degenerative disease.~* Anemia (Hb\<12 g/dl).~* Uncontrolled blood pressure.~* Use of any drugs able to interfere with the study medications

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): ezetimibe tablets 10 mg/die + simvastatin tablets 20 mg/die six weeks
- 2 (Type: PLACEBO_COMPARATOR): placebo + simvastatin tablets 20 mg/die six weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).